Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Clinical Trial Research
Research in the area of clinical trial research reported from TargeGen
May 16th, 2008
New investigation results, 'Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degeneration,' are detailed in a study published in Journal of Medicinal Chemistry. "Age-related macular degeneration (AMD) is one of the leading causes of loss of vision in the industrialized world. Attenuating the VEGF signal in the eye to treat AMD has been validated clinically," scientists writing in the Journal of Medicinal Chemistry report. "A large body of evidence suggests that...
Source: Health Business Week (2008-05-16)
|
